
Opinion|Videos|November 27, 2024
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
AI-generated profiles impersonate female urologists to market ED products online
2
John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC
3
Doublet or triplet? Urologists weighs in on mCSPC options
4
Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD
5






